Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455429 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Terminated
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT00455429 is a Phase 2 study that was terminated before completion, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 84 participants.
The verdict
NCT00455429, a Phase 2 study, was terminated before completion, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of four dose regimens (pattern of giving treatment) of JNJ-26113100 in the treatment of adult Atopic Dermatitis (\[AD\]; skin rash, inflammation) that is moderate in severity.
Interventions
- DRUG Placebo
- DRUG JNJ-26113100 (50 mg) once daily
- DRUG JNJ-26113100 (100 mg) once daily
- DRUG JNJ-26113100 (100 mg) twice daily
- DRUG JNJ-26113100 (250 mg) twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00455429
The ClinicalTrials.gov registry entry for NCT00455429 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00455429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00455429 about?
NCT00455429 is a clinical study titled "An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis". The purpose of this study is to evaluate the safety and effectiveness of four dose regimens (pattern of giving treatment) of JNJ-26113100 in the treatment of adult Atopic Dermatitis (\[AD\]; skin rash, inflammation) that is moderate in severity.
What is the current status of trial NCT00455429?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2007-04. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00455429?
The interventions under investigation include: Placebo (DRUG), JNJ-26113100 (50 mg) once daily (DRUG), JNJ-26113100 (100 mg) once daily (DRUG), JNJ-26113100 (100 mg) twice daily (DRUG), JNJ-26113100 (250 mg) twice daily (DRUG).
Who is sponsoring clinical trial NCT00455429?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.